Upsher-Smith Laboratories, Inc.
14905 23rd Avenue North
194 articles with Upsher-Smith Laboratories, Inc.
Upsher-Smith Enters Into Exclusive Marketing And Distribution Agreement For Six Ophthalmic/Otic ANDAs
Upsher-Smith Laboratories, LLC (Upsher-Smith) announced that it has entered into an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products.
Upsher-Smith Laboratories, LLC announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg.
Upsher-Smith Launches New Access Pathways® Platinum Pass At 2018 American Academy Of Neurology Annual Meeting
Upsher-Smith Laboratories, LLC announced that it will be featuring Platinum Pass, the latest addition to the Access Pathways® Program for Qudexy® XR (topiramate) extended-release capsules at the 70th Annual Meeting of the American Academy of Neurology (AAN), April 21-27, 2018, in Los Angeles, CA.
Upsher-Smith today announced that it has received FDA approval of its ANDA for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg.
Upsher-Smith's Parent Company Completes Stake Transfer to Sumitomo Corporation in U.S. Generics Market
Upsher-Smith today reported that on January 3, 2018, its parent company, Sawai successfully completed the sale of a 20 percent stake in Sawai America, LLC to Sumitomo Corporation of Americas.
The Company received approval of an ANDA from the FDA for this product, which will be marketed and distributed by Upsher-Smith.
The transaction is expected to close by the end of March 2018.
Upsher-Smith's Parent Company Enters Into Agreement With Astra to Manufacture And Market Migraine Medication in Japan
Upsher-Smith today reported that Sawai has entered into an exclusive agreement with Astra to manufacture and market Zomig Tablets 2.5 mg and Zomig RM Tablets 2.5 mg, a migraine medication in Japan designed to melt quickly in the mouth.
Upsher-Smith Laboratories Launches Newly Designed Website For Qudexy XR (topiramate) Extended-Release Capsules
Upsher-Smith Laboratories Release: FDA Approves Expanded Indication For Qudexy XR (Topiramate) Extended-Release Capsules To Include Prophylaxis Of Migraine Headache In Adults And Adolescents
Upsher-Smith Laboratories Enters Agreement To Expand Marketing And Distribution Of Generic Products For U.S. Market
Upsher-Smith Laboratories Presents Data Characterizing The Pharmacokinetics And Safety/Tolerability Of Investigational Midazolam Nasal Spray (Usl261) In Pediatric Participants With Epilepsy
Upsher-Smith Laboratories Enters Into Exclusive Development And Distribution Agreement With Pharmathen
Upsher-Smith Laboratories Launches "It's That Simple" Program For Qudexy XR (topiramate) Extended-Release Capsules
Upsher-Smith Laboratories Enters Into Exclusive Marketing And Distribution Agreement With Emerging Pharmaceutical Company